Stop putting toll booths on the information highway

The New York Times reported last month that Senator Charles Grassley (R-Iowa) is furious with the FDA's recent tactics. Grassley said, "They think they can be the Gestapo and do anything they want." Once again, federal agencies that should be leading the changes in healthcare are getting in the way and at a critical time.

Improvements and changes in the delivery of healthcare must come on the front lines – at the ‘micro’ level where individual patients and providers meet.  Changes at the ‘macro’ level in Washington are unlikely to occur.


Focus must now turn to getting exchanges right, cutting healthcare costs

In the wake of the Supreme Court’s decision upholding the individual mandate but restricting the federal government’s ability to incentivize expansion of Medicaid, reform efforts on the federal level must focus on three major areas: 1) getting states to expand Medicaid, 2) launching the exchanges, and, most importantly, 3) expanding and accelerating efforts to control health care costs.


EPA jeopardizing health of asthmatics

For the almost 20 years I served in Congress, much of my focus was on healthcare issues and holding federal regulators accountable for ensuring the safety and well-being of Americans.


Blueprint for dismantling 'ObamaCare'

Here’s the blueprint for how the states can eviscerate three central pillars of ObamaCare, crippling it and set the stage for replacing it if Mitt Romney takes the White House and the GOP takes the Senate this November.


PEPFAR's vital role in the fight against AIDS

To a large degree, the International AIDS Conference under way in Washington, DC, is a celebration of life. Yes, the deadly disease continues to loom over our world, with no known cure. But HIV/ AIDS is no longer a death sentence—for those who realize that they have the disease and have access to life saving medicines. After doctors began treating HIV with powerful combinations of antiretroviral drugs in 1996, life expectancies for those infected changed from months to a full, normal span.


Ending U.S. chimpanzee laboratories will save chimpanzee research

When members of the Senate’s Environment and Public Works Committee meet Wednesday to mark up the bipartisan Great Ape Protection and Cost Savings Act, S. 810/H.R. 1513, I urge them to approve this bill that validates the long standing conclusions of the majority of chimpanzee researchers that non-laboratory based research will contribute most to improving human health, is more humane and promotes chimpanzee conservation. As professor of evolutionary anthropology and cognitive neuroscience at Duke University, and director of the Hominoid Psychology Research Group, I lead researchers studying chimpanzees in African sanctuaries, the wild and U.S. zoos. The majority of chimpanzee researchers are like us and do not conduct research in the obsolete U.S. chimpanzee laboratories. Research groups like mine exist at Duke, Emory, U Penn, UCLA, UCSD, Michigan U, Yale, and Harvard to name a few.


How we'll end AIDS in America

HIV/AIDS will pass into history when current scientific breakthroughs are delivered to scale rapidly, effectively and efficiently to our friends, our loved ones, and our communities at large.

We’re getting closer, but we’re not close enough.


Is HIV/AIDS financing insufficient?

That is a billion dollar question when we face other competing priorities like heart diseases, diabetes, maternal health, and cancer. The political leaders are talking about AIDS free generation. Whether this is possible or not is another debate but it is a laudable goal. It is possible to have 15 million AIDS patients on treatment by 2015, thus ensuring close to universal access to treatment we dream of. There is also huge cry for more funds. The International AIDS Conference in July 2012 will debate this and other issues. However, serious rethinking must be done and each donor must ask, Is funding for HIV/AIDS sufficient? I think it is. Here is why?